A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece.
abobotulinumtoxinA
budget impact analysis
cost-effectiveness analysis
limb spasticity
Journal
Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765
Informations de publication
Date de publication:
08 09 2023
08 09 2023
Historique:
received:
23
07
2023
revised:
16
08
2023
accepted:
22
08
2023
medline:
28
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
This study aimed to assess the cost-effectiveness of abobotulinumtoxinA (aboBoNT-A) plus Best Supportive Care (BSC) compared with BSC alone for managing limb spasticity in adult patients in Greece, as well as to conduct a budget impact analysis of the introduction of aboBoNT-A in the Greek healthcare system compared to onabotulinumtoxinA (onaBoNT-A). Clinical studies were utilized to extract data on drug efficacy and patients' utility, while cost data were collected from Greek sources. The results of the study showed that aboBoNT-A plus BSC was a cost-effective treatment option for both upper and lower limb spasticity in adult patients compared to BSC. Additionally, introducing aboBoNT-A into the Greek healthcare system resulted in cost savings in pharmaceutical spending over a 5-year period. The findings suggest that incorporating aboBoNT-A into the Greek healthcare system could improve patient access to treatment and healthcare resource efficiency, as it is a more economical option compared to onaBoNT-A.
Identifiants
pubmed: 37755987
pii: toxins15090561
doi: 10.3390/toxins15090561
pmc: PMC10534563
pii:
doi:
Substances chimiques
abobotulinumtoxinA
EC 3.4.24.69
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Med Econ. 2021 Jan-Dec;24(1):949-961
pubmed: 34340647
J Rehabil Med. 2022 Aug 24;54:jrm00303
pubmed: 35844200
JMIR Public Health Surveill. 2020 Dec 7;6(4):e17928
pubmed: 33284124
Lancet Neurol. 2015 Oct;14(10):992-1001
pubmed: 26318836
Eur J Neurol. 2013 May;20(5):773-80
pubmed: 23278954
Saudi J Anaesth. 2013 Oct;7(4):453-60
pubmed: 24348300
Value Health. 2014 Jan-Feb;17(1):5-14
pubmed: 24438712
Medicine (Baltimore). 2016 Jan;95(2):e2468
pubmed: 26765447
Neuropsychiatr Dis Treat. 2014 Jan 23;10:111-22
pubmed: 24482572
Clinicoecon Outcomes Res. 2015 Apr 01;7:185-93
pubmed: 25878510
Neurology. 2017 Nov 28;89(22):2245-2253
pubmed: 29093068
J Neurol. 2018 Apr;265(4):856-862
pubmed: 29423615
BMC Neurol. 2013 Sep 08;13:118
pubmed: 24011236
J Med Econ. 2022 Jan-Dec;25(1):919-929
pubmed: 35730362
Health Qual Life Outcomes. 2015 Sep 29;13:159
pubmed: 26415945
Clin Interv Aging. 2015 Nov 06;10:1793-802
pubmed: 26609225
PM R. 2017 Dec;9(12):1181-1190
pubmed: 28625615
Value Health. 2014 Nov;17(7):A479-80
pubmed: 27201392